Otelixizumab Completed Phase 1 Trials for Type 1 Diabetes Mellitus Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00946257Subcutaneous Administration of Otelixizumab to T1DM Patients